The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Open accessAbstract
PURPOSE: KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer. PATIENTS AND METHODS: Patients received pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician or patient decision. Tumor imaging was performed every 9 weeks for the first 12 months and every 12 weeks thereafter. The primary end point was objective response rate (ORR), assessed per Response Evaluation Criteria in Solid Tumors (version 1.1) by independent central radiologic review. Safety was a secondary end point. RESULTS: Ninety-eight patients were treated. Median age was 46.0 years (range, 24 to 75 years), and 65.3% of patients had Eastern Cooperative Oncology Group performance status of 1. Eighty-two patients (83.7%) had programmed death-ligand 1 (PD-L1)–positive tumors (combined positive score ≥ 1), 77 having previously received one or more lines of chemotherapy for recurrent or metastatic disease. Median follow-up was 10.2 months (range, 0.6 to 22.7 months). ORR was 12.2% (95% CI, 6.5% to 20.4%), with three complete and nine partial responses. All 12 responses were in patients with PD-L1–positive tumors, for an ORR of 14.6% (95% CI, 7.8% to 24.2%); 14.3% (95% CI, 7.4% to 24.1%) of these responses were in those who had received one or more lines of chemotherapy for recurrent or metastatic disease. Median duration of response was not reached (range, ≥ 3.7 to ≥ 18.6 months). Treatment-related adverse events occurred in 65.3% of patients, and the most common were hypothyroidism (10.2%), decreased appetite (9.2%), and fatigue (9.2%). Treatment-related grade 3 to 4 adverse events occurred in 12.2% of patients. CONCLUSION: Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer. On the basis of these results, the US Food and Drug Administration granted accelerated approval of pembrolizumab for patients with advanced PD-L1–positive cervical cancer who experienced progression during or after chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8909 · Cited by 693
Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31607-0 · Cited by 684
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Long, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.021 · Cited by 556
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Self-citationMolecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 407
Bonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.8.1079 · Cited by 402
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311
Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 310
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 225
Changing paradigms in the systemic treatment of advanced cervical cancer
Pfaendler, K. S., & Tewari, K. S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.07.022 · Cited by 221
Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N., & Pentheroudakis, G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 174
Lheureux, S., Butler, M. O., Clarke, B., Cristea, M. C., Martin, L. P., Tonkin, K., Fleming, G. F., Tinker, A. V., Hirte, H. W., Tsoref, D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3776 · Cited by 160
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
Minion, L. E., & Tewari, K. S. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.009 · Cited by 128
Bookman, M. A., Blessing, J. A., Hanjani, P., Herzog, T. J., & Andersen, W. A. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5807 · Cited by 125
Targeted Gene Delivery Therapies for Cervical Cancer
Ayén, Á., Jiménez-Martínez, Y., & Boulaiz, H. (2020) · Cancers · doi:10.3390/cancers12051301 · Cited by 66
Immune check-point in cervical cancer
Felice, F. D., Marchetti, C., Palaia, I., Ostuni, R., Muzii, L., Tombolini, V., & Panici, P. B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.006 · Cited by 58
Pothuri, B., Secord, A. A., Armstrong, D. K., Chan, J. K., Fader, A. N., Huh, W. K., Kesterson, J. P., Liu, J. F., Moore, K. N., Westin, S. N., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.04.694 · Cited by 56
Gearing up T-cell immunotherapy in cervical cancer
Chauhan, S. R., & Bharadwaj, M. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.04.001 · Cited by 22
Major clinical research advances in gynecologic cancer in 2019
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Lee, J., Lee, Y.-Y., Hansen, H. F., Mirza, M. R., & Kim, J. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e48 · Cited by 19
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
Frega, S., Maso, A. D., Pasello, G., Cuppari, L., Bonanno, L., Conte, P., & Evangelista, L. (2020) · Cancers · doi:10.3390/cancers12051303 · Cited by 10
Cited by
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Tewari, K. S., Salman, P., Hoyos Usta, E., Yañez, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112435 · Cited by 1,067
Self-citationDavis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Metadata
- Authors
- Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., Pruitt, S. K., & Leary, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-10
- Volume
- 37
- Issue
- 17
- Pages
- 1470-1478
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2925815206
- Cited by
- 1,069
- References
- 29
- FWCI
- 46.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.